Dec 30, 2025 | Benefits preservation, Biosimilars, Client Feedback, Client Surveys, Direct-to-Employer Contracting, Forensic claims review, Innovations, Kurt Harden, MedBen Employees, Self-funding, Spending, Third party administration
On behalf of the MedBen team, I wish you a happy and healthy new year, and thank you for your continued trust in MedBen. Our commitment remains to be the benefits partner that employers prefer, and we value the opportunity to serve you. In my 35 years with MedBen,...
Dec 31, 2024 | Client Feedback, Client Services, Client Surveys, Innovations, Kurt Harden, Self-funding, Stability, Third party administration, Transparency
On behalf of the MedBen team, I wish you all the best for the new year and thank you for your continued trust in MedBen. While MedBen has been serving employer groups since 1938, this past year our company marked 35 years of providing third party administration to...
Oct 14, 2024 | Alternative Reimbursement Strategies, Forensic claims review, Kurt Harden, MedBen News, Pharmacogenomics, Precision medicine, Quality, Wellness
On October 1, MedBen Chairman and CEO Kurt Harden spoke on the topic “A Third-Party Payer’s Approach to Providing Quality Care While Minimizing Cost” at the 2024 Ventegra Client Conference. Ventegra serves as MedBen Rx’s pharmacy benefits partner....
Oct 1, 2024 | Genomics, Kurt Harden, MedBen News, Nutrigenomics, Pharmacogenomics, Pharmacy, Wellness
MedBen Chairman & CEO Kurt Harden and Profero Team Director of Precision Medicine Cynthia Yu were featured presenters at the 11th Annual Sherrill-Morgan Healthcare Innovation Conference on September 18th. Harden and Yu spoke on the topic of genomic testing — what...
May 29, 2024 | Announcements, Caroline Fraker, Doug Freeman, Kurt Harden, MedBen Board of Directors, MedBen Employees
At the recent Annual Meeting for MedBen, Doug Freeman, who for over 36 years served as President and later Chairman of Medical Benefits Mutual Life Insurance Co. (MedBen), retired from the Board of Directors. At the same meeting, Kurt Harden, previously MedBen’s...
May 13, 2024 | Diabetes, Kurt Harden, MedBen Rx, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
